| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biometry | 18 | 2019 | 558 | 2.740 |
Why?
|
| Models, Statistical | 27 | 2022 | 5102 | 2.450 |
Why?
|
| Survival Analysis | 26 | 2022 | 10250 | 1.980 |
Why?
|
| Alzheimer Disease | 43 | 2023 | 8037 | 1.810 |
Why?
|
| Likelihood Functions | 16 | 2019 | 1005 | 1.750 |
Why?
|
| Research Design | 13 | 2019 | 5987 | 1.400 |
Why?
|
| Proportional Hazards Models | 24 | 2020 | 12355 | 1.320 |
Why?
|
| Data Interpretation, Statistical | 15 | 2019 | 2715 | 1.190 |
Why?
|
| Computer Simulation | 24 | 2023 | 6196 | 1.140 |
Why?
|
| Clinical Trials as Topic | 14 | 2017 | 7908 | 1.100 |
Why?
|
| Statistics, Nonparametric | 6 | 2016 | 2886 | 1.000 |
Why?
|
| Comparative Genomic Hybridization | 5 | 2016 | 496 | 0.930 |
Why?
|
| Biostatistics | 2 | 2015 | 162 | 0.930 |
Why?
|
| Neurofibrillary Tangles | 6 | 2022 | 439 | 0.870 |
Why?
|
| Amyloid beta-Peptides | 23 | 2023 | 3585 | 0.830 |
Why?
|
| Plaque, Amyloid | 11 | 2020 | 729 | 0.800 |
Why?
|
| Oligodendroglioma | 13 | 2010 | 279 | 0.740 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2020 | 9960 | 0.730 |
Why?
|
| Disease Progression | 24 | 2023 | 13280 | 0.700 |
Why?
|
| Bayes Theorem | 3 | 2017 | 2309 | 0.610 |
Why?
|
| Clinical Trials, Phase III as Topic | 3 | 2013 | 840 | 0.600 |
Why?
|
| Accidents, Traffic | 2 | 2013 | 819 | 0.590 |
Why?
|
| Facial Paralysis | 1 | 2021 | 338 | 0.590 |
Why?
|
| tau Proteins | 9 | 2022 | 1868 | 0.590 |
Why?
|
| DNA Copy Number Variations | 4 | 2016 | 1940 | 0.580 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 3 | 2013 | 520 | 0.580 |
Why?
|
| Apolipoprotein E4 | 6 | 2022 | 668 | 0.550 |
Why?
|
| Wounds and Injuries | 3 | 2013 | 2400 | 0.540 |
Why?
|
| Brain Neoplasms | 26 | 2018 | 8860 | 0.540 |
Why?
|
| Humans | 234 | 2023 | 744220 | 0.520 |
Why?
|
| Statistics as Topic | 3 | 2017 | 2374 | 0.520 |
Why?
|
| Parkinson Disease | 7 | 2018 | 2776 | 0.510 |
Why?
|
| Cerebral Amyloid Angiopathy | 10 | 2015 | 859 | 0.490 |
Why?
|
| Epidemics | 1 | 2020 | 523 | 0.490 |
Why?
|
| Regression Analysis | 9 | 2019 | 6461 | 0.480 |
Why?
|
| Mortality | 2 | 2016 | 2864 | 0.480 |
Why?
|
| Apolipoproteins E | 9 | 2022 | 1438 | 0.480 |
Why?
|
| Case-Control Studies | 12 | 2019 | 21752 | 0.460 |
Why?
|
| Specimen Handling | 4 | 2012 | 694 | 0.460 |
Why?
|
| Research Subjects | 1 | 2015 | 239 | 0.450 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2015 | 264 | 0.440 |
Why?
|
| Sample Size | 6 | 2014 | 846 | 0.440 |
Why?
|
| Propylene Glycols | 1 | 2013 | 92 | 0.440 |
Why?
|
| Probability | 6 | 2022 | 2505 | 0.440 |
Why?
|
| Brain | 28 | 2022 | 26413 | 0.430 |
Why?
|
| Controlled Clinical Trials as Topic | 3 | 1997 | 187 | 0.420 |
Why?
|
| Glioma | 9 | 2012 | 3401 | 0.410 |
Why?
|
| Rural Health | 1 | 2013 | 305 | 0.410 |
Why?
|
| Acute Kidney Injury | 9 | 2017 | 1971 | 0.410 |
Why?
|
| Glioblastoma | 13 | 2018 | 3481 | 0.410 |
Why?
|
| Markov Chains | 4 | 2012 | 969 | 0.390 |
Why?
|
| Algorithms | 13 | 2018 | 13885 | 0.390 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 783 | 0.380 |
Why?
|
| Neurosciences | 1 | 2015 | 348 | 0.380 |
Why?
|
| Genome, Human | 3 | 2016 | 4420 | 0.380 |
Why?
|
| Logistic Models | 10 | 2019 | 13409 | 0.380 |
Why?
|
| Adipokines | 3 | 2012 | 319 | 0.380 |
Why?
|
| Longitudinal Studies | 13 | 2022 | 13990 | 0.380 |
Why?
|
| Lectins | 3 | 2012 | 513 | 0.380 |
Why?
|
| Sphingosine | 1 | 2013 | 307 | 0.380 |
Why?
|
| Age of Onset | 8 | 2018 | 3270 | 0.370 |
Why?
|
| Models, Genetic | 5 | 2006 | 3494 | 0.370 |
Why?
|
| Aged | 95 | 2023 | 163253 | 0.360 |
Why?
|
| Cluster Analysis | 3 | 2009 | 2715 | 0.360 |
Why?
|
| Linear Models | 3 | 2018 | 5953 | 0.360 |
Why?
|
| Rural Health Services | 1 | 2013 | 379 | 0.350 |
Why?
|
| Aged, 80 and over | 58 | 2022 | 57768 | 0.350 |
Why?
|
| Homicide | 1 | 2012 | 287 | 0.340 |
Why?
|
| Amyloid | 5 | 2016 | 795 | 0.340 |
Why?
|
| Diagnostic Errors | 4 | 2013 | 1255 | 0.340 |
Why?
|
| Vaccination | 1 | 2021 | 3278 | 0.330 |
Why?
|
| Amyloidosis | 5 | 2019 | 795 | 0.330 |
Why?
|
| Genomics | 4 | 2022 | 5722 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 1 | 9 | 2012 | 658 | 0.320 |
Why?
|
| Histology | 1 | 2007 | 16 | 0.320 |
Why?
|
| Placebos | 1 | 2013 | 1677 | 0.320 |
Why?
|
| Apolipoprotein E2 | 2 | 2021 | 127 | 0.320 |
Why?
|
| Neurology | 1 | 2015 | 764 | 0.300 |
Why?
|
| Trauma Centers | 1 | 2012 | 889 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2018 | 17449 | 0.290 |
Why?
|
| Monte Carlo Method | 6 | 2014 | 1254 | 0.290 |
Why?
|
| Male | 116 | 2023 | 350027 | 0.280 |
Why?
|
| Dementia | 5 | 2022 | 2518 | 0.280 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 105 | 0.270 |
Why?
|
| Female | 120 | 2022 | 380197 | 0.270 |
Why?
|
| Stroke | 8 | 2018 | 9981 | 0.260 |
Why?
|
| Positron-Emission Tomography | 11 | 2023 | 6274 | 0.260 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2007 | 214 | 0.260 |
Why?
|
| Numerical Analysis, Computer-Assisted | 2 | 2002 | 125 | 0.260 |
Why?
|
| Neurilemmoma | 2 | 2008 | 547 | 0.260 |
Why?
|
| Calcineurin | 2 | 2018 | 226 | 0.250 |
Why?
|
| Pneumonia | 2 | 2013 | 2134 | 0.250 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2005 | 657 | 0.250 |
Why?
|
| Emergency Medical Services | 2 | 2013 | 1916 | 0.250 |
Why?
|
| Mucolipidoses | 2 | 2015 | 82 | 0.250 |
Why?
|
| Cross Infection | 1 | 2013 | 1416 | 0.240 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 1375 | 0.240 |
Why?
|
| Follow-Up Studies | 11 | 2023 | 39045 | 0.240 |
Why?
|
| Immunosuppressive Agents | 3 | 2013 | 4151 | 0.230 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 628 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 5 | 2013 | 895 | 0.230 |
Why?
|
| Immunohistochemistry | 16 | 2018 | 11368 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 19 | 6 | 2009 | 367 | 0.220 |
Why?
|
| Genotype | 9 | 2021 | 12956 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2013 | 2234 | 0.220 |
Why?
|
| Middle Aged | 76 | 2023 | 213367 | 0.220 |
Why?
|
| Lymphoma | 5 | 2013 | 1873 | 0.210 |
Why?
|
| Learning Curve | 1 | 2023 | 208 | 0.210 |
Why?
|
| Dermatology | 2 | 2023 | 872 | 0.210 |
Why?
|
| Family Health | 1 | 2007 | 1282 | 0.200 |
Why?
|
| Aniline Compounds | 6 | 2017 | 986 | 0.200 |
Why?
|
| Creatinine | 3 | 2013 | 1919 | 0.200 |
Why?
|
| Meningeal Neoplasms | 4 | 2013 | 1241 | 0.200 |
Why?
|
| Neuropsychological Tests | 9 | 2022 | 6991 | 0.200 |
Why?
|
| Cognition | 6 | 2022 | 6765 | 0.200 |
Why?
|
| Physical Fitness | 1 | 2006 | 733 | 0.200 |
Why?
|
| Siblings | 1 | 2006 | 854 | 0.200 |
Why?
|
| Suicide | 1 | 2012 | 1477 | 0.200 |
Why?
|
| Hemophilia A | 5 | 2003 | 351 | 0.200 |
Why?
|
| Fallopian Tubes | 2 | 2012 | 182 | 0.200 |
Why?
|
| Genetic Markers | 5 | 2008 | 2634 | 0.190 |
Why?
|
| Meningioma | 4 | 2012 | 1209 | 0.190 |
Why?
|
| Virus Latency | 2 | 2019 | 358 | 0.190 |
Why?
|
| Sequence Analysis, DNA | 2 | 2013 | 4803 | 0.190 |
Why?
|
| Optic Nerve | 2 | 2015 | 556 | 0.190 |
Why?
|
| Mice, Transgenic | 17 | 2019 | 9735 | 0.190 |
Why?
|
| Platelet Function Tests | 1 | 2022 | 270 | 0.190 |
Why?
|
| Cognition Disorders | 4 | 2016 | 4041 | 0.190 |
Why?
|
| Genetic Linkage | 1 | 2006 | 2422 | 0.190 |
Why?
|
| DNA, Neoplasm | 5 | 2009 | 1758 | 0.180 |
Why?
|
| Tauopathies | 2 | 2014 | 307 | 0.180 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2012 | 602 | 0.180 |
Why?
|
| Time Factors | 16 | 2019 | 40063 | 0.180 |
Why?
|
| Odds Ratio | 5 | 2018 | 9849 | 0.180 |
Why?
|
| Neurons | 9 | 2019 | 9335 | 0.180 |
Why?
|
| Gene Expression Profiling | 8 | 2022 | 9438 | 0.180 |
Why?
|
| Synapses | 4 | 2019 | 1729 | 0.180 |
Why?
|
| Anterior Cruciate Ligament | 1 | 2023 | 415 | 0.180 |
Why?
|
| Adult | 58 | 2023 | 214035 | 0.180 |
Why?
|
| Paraffin Embedding | 3 | 2012 | 299 | 0.180 |
Why?
|
| Neoplasms | 6 | 2019 | 21672 | 0.180 |
Why?
|
| Confidence Intervals | 6 | 2018 | 2970 | 0.180 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 1582 | 0.170 |
Why?
|
| Cerebral Hemorrhage | 4 | 2022 | 2647 | 0.170 |
Why?
|
| Multiple System Atrophy | 1 | 2021 | 122 | 0.170 |
Why?
|
| Twins | 1 | 2001 | 339 | 0.170 |
Why?
|
| Prognosis | 25 | 2020 | 29050 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 638 | 0.160 |
Why?
|
| Family | 4 | 2014 | 3148 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2019 | 265 | 0.160 |
Why?
|
| Cellulitis | 1 | 2020 | 206 | 0.160 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2010 | 126 | 0.160 |
Why?
|
| Software | 5 | 2018 | 4442 | 0.160 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 45 | 0.160 |
Why?
|
| Astrocytes | 5 | 2015 | 1270 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2015 | 6535 | 0.160 |
Why?
|
| Autopsy | 3 | 2017 | 1021 | 0.160 |
Why?
|
| Intracranial Hemorrhages | 3 | 2018 | 855 | 0.160 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2018 | 68 | 0.160 |
Why?
|
| Appointments and Schedules | 1 | 2002 | 417 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 3158 | 0.160 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2012 | 450 | 0.160 |
Why?
|
| Weights and Measures | 2 | 2008 | 43 | 0.160 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2018 | 1261 | 0.160 |
Why?
|
| Visual Cortex | 2 | 2019 | 1149 | 0.150 |
Why?
|
| Hypotension, Orthostatic | 1 | 2021 | 255 | 0.150 |
Why?
|
| Microglia | 4 | 2015 | 1266 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2014 | 9230 | 0.150 |
Why?
|
| Rheumatology | 1 | 2023 | 576 | 0.150 |
Why?
|
| Retrospective Studies | 28 | 2023 | 77426 | 0.150 |
Why?
|
| Chromosome Aberrations | 4 | 2012 | 1814 | 0.150 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 412 | 0.150 |
Why?
|
| Gene Dosage | 3 | 2011 | 1251 | 0.150 |
Why?
|
| Alopecia | 1 | 2021 | 381 | 0.150 |
Why?
|
| Piperidines | 2 | 2023 | 1605 | 0.150 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2021 | 459 | 0.150 |
Why?
|
| Aging | 6 | 2019 | 8661 | 0.140 |
Why?
|
| Brain Ischemia | 3 | 2018 | 3265 | 0.140 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2018 | 215 | 0.140 |
Why?
|
| Methylphenidate | 1 | 2020 | 473 | 0.140 |
Why?
|
| Olfactory Perception | 1 | 2016 | 54 | 0.140 |
Why?
|
| Amyloidogenic Proteins | 1 | 2017 | 152 | 0.140 |
Why?
|
| Antigens, CD19 | 1 | 1999 | 380 | 0.140 |
Why?
|
| Bioethics | 1 | 1997 | 116 | 0.140 |
Why?
|
| Calibration | 1 | 2018 | 816 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5138 | 0.140 |
Why?
|
| Medical Staff, Hospital | 1 | 2020 | 603 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2016 | 3921 | 0.140 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 282 | 0.140 |
Why?
|
| Treatment Failure | 1 | 2002 | 2619 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2007 | 2265 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2012 | 4328 | 0.130 |
Why?
|
| Vitamin D | 2 | 2019 | 3222 | 0.130 |
Why?
|
| Metformin | 1 | 2022 | 835 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 611 | 0.130 |
Why?
|
| Linkage Disequilibrium | 1 | 2000 | 1997 | 0.130 |
Why?
|
| Cicatrix | 1 | 2021 | 764 | 0.130 |
Why?
|
| Memory | 2 | 2023 | 2174 | 0.130 |
Why?
|
| 2,3-Diphosphoglycerate | 1 | 2014 | 15 | 0.130 |
Why?
|
| Health | 1 | 2018 | 394 | 0.130 |
Why?
|
| Epidemiologic Methods | 1 | 2000 | 1365 | 0.130 |
Why?
|
| Retinal Dystrophies | 1 | 2015 | 58 | 0.130 |
Why?
|
| Cohort Studies | 18 | 2023 | 40559 | 0.130 |
Why?
|
| Nerve Degeneration | 2 | 2012 | 748 | 0.130 |
Why?
|
| PAX2 Transcription Factor | 2 | 2012 | 80 | 0.130 |
Why?
|
| Alleles | 5 | 2015 | 6938 | 0.130 |
Why?
|
| Hospital Mortality | 4 | 2022 | 5316 | 0.130 |
Why?
|
| HIV Infections | 11 | 2019 | 16718 | 0.130 |
Why?
|
| Chest Pain | 1 | 2022 | 1114 | 0.130 |
Why?
|
| Renal Replacement Therapy | 2 | 2014 | 258 | 0.120 |
Why?
|
| Malpractice | 1 | 2020 | 572 | 0.120 |
Why?
|
| NFATC Transcription Factors | 2 | 2018 | 381 | 0.120 |
Why?
|
| Mosaicism | 3 | 2012 | 441 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 12244 | 0.120 |
Why?
|
| Memory Disorders | 2 | 2023 | 1184 | 0.120 |
Why?
|
| AIDS-Related Complex | 1 | 2014 | 111 | 0.120 |
Why?
|
| Hospitals | 2 | 2020 | 3952 | 0.120 |
Why?
|
| Knee Joint | 1 | 2023 | 1680 | 0.120 |
Why?
|
| Dental Impression Materials | 1 | 2014 | 36 | 0.120 |
Why?
|
| Gliosis | 2 | 2014 | 245 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 15525 | 0.120 |
Why?
|
| Renal Dialysis | 4 | 2016 | 1787 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 3 | 2007 | 1380 | 0.120 |
Why?
|
| Microvessels | 1 | 2018 | 544 | 0.120 |
Why?
|
| Twins, Monozygotic | 2 | 2009 | 458 | 0.120 |
Why?
|
| Hypophosphatemia | 1 | 2014 | 85 | 0.120 |
Why?
|
| Carbolines | 1 | 2015 | 265 | 0.120 |
Why?
|
| Home Care Services | 1 | 2020 | 606 | 0.120 |
Why?
|
| Risk | 5 | 2023 | 9685 | 0.120 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2016 | 367 | 0.120 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 3 | 2015 | 271 | 0.120 |
Why?
|
| DNA, Mitochondrial | 2 | 2012 | 817 | 0.120 |
Why?
|
| Dental Impression Technique | 1 | 2014 | 60 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 15161 | 0.120 |
Why?
|
| Chromosome Deletion | 3 | 2009 | 1401 | 0.110 |
Why?
|
| Disease Models, Animal | 12 | 2019 | 18027 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2012 | 2649 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2014 | 2702 | 0.110 |
Why?
|
| Caffeine | 1 | 2018 | 699 | 0.110 |
Why?
|
| Nervous System Diseases | 2 | 2014 | 1623 | 0.110 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2006 | 659 | 0.110 |
Why?
|
| Amyloid beta-Protein Precursor | 4 | 2019 | 1121 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 2032 | 0.110 |
Why?
|
| Dendrites | 2 | 2012 | 485 | 0.110 |
Why?
|
| Dendritic Spines | 2 | 2013 | 233 | 0.110 |
Why?
|
| Receptors, Virus | 2 | 2014 | 648 | 0.110 |
Why?
|
| Models, Biological | 5 | 2020 | 9582 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2008 | 640 | 0.110 |
Why?
|
| Adolescent | 24 | 2021 | 85759 | 0.110 |
Why?
|
| Treatment Outcome | 18 | 2021 | 63119 | 0.110 |
Why?
|
| Prospective Studies | 16 | 2023 | 53280 | 0.110 |
Why?
|
| Antibodies | 2 | 2014 | 2461 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2017 | 8950 | 0.110 |
Why?
|
| Sensitivity and Specificity | 8 | 2017 | 14726 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 2170 | 0.110 |
Why?
|
| Adenovirus Infections, Human | 1 | 2013 | 71 | 0.110 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2013 | 150 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 3509 | 0.110 |
Why?
|
| Calcium Signaling | 1 | 2017 | 721 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 895 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2000 | 2617 | 0.110 |
Why?
|
| Dental Prosthesis Design | 1 | 2014 | 259 | 0.110 |
Why?
|
| Computer-Aided Design | 1 | 2014 | 298 | 0.110 |
Why?
|
| Agglutinins | 2 | 2002 | 29 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2021 | 1065 | 0.100 |
Why?
|
| HIV | 1 | 2019 | 1604 | 0.100 |
Why?
|
| Extracellular Fluid | 1 | 2013 | 167 | 0.100 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 6352 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 551 | 0.100 |
Why?
|
| Corpus Striatum | 1 | 2018 | 1220 | 0.100 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2011 | 379 | 0.100 |
Why?
|
| Cytomegalovirus | 3 | 2002 | 732 | 0.100 |
Why?
|
| Boston | 4 | 2023 | 9311 | 0.100 |
Why?
|
| Young Adult | 15 | 2022 | 56436 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2023 | 2940 | 0.100 |
Why?
|
| Formaldehyde | 2 | 2010 | 353 | 0.100 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2021 | 1432 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2017 | 2017 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2002 | 2684 | 0.100 |
Why?
|
| United States | 10 | 2020 | 69867 | 0.100 |
Why?
|
| Loss of Heterozygosity | 4 | 2006 | 684 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2002 | 2559 | 0.100 |
Why?
|
| Methotrexate | 3 | 2008 | 1720 | 0.100 |
Why?
|
| Prevalence | 4 | 2017 | 15226 | 0.100 |
Why?
|
| Membrane Glycoproteins | 3 | 2014 | 3769 | 0.100 |
Why?
|
| Pathology, Surgical | 1 | 2012 | 155 | 0.100 |
Why?
|
| Neuroglia | 4 | 2019 | 927 | 0.100 |
Why?
|
| Thiazoles | 5 | 2017 | 1484 | 0.100 |
Why?
|
| Mutation | 12 | 2022 | 29784 | 0.100 |
Why?
|
| Fixatives | 1 | 2010 | 94 | 0.100 |
Why?
|
| Adenoviruses, Human | 1 | 2013 | 257 | 0.100 |
Why?
|
| Risk Factors | 18 | 2022 | 72280 | 0.090 |
Why?
|
| Mice | 23 | 2019 | 81178 | 0.090 |
Why?
|
| Predictive Value of Tests | 12 | 2012 | 15070 | 0.090 |
Why?
|
| Reproducibility of Results | 8 | 2023 | 19907 | 0.090 |
Why?
|
| Vitamins | 1 | 2019 | 1621 | 0.090 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2016 | 1537 | 0.090 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 2005 | 249 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 1999 | 1401 | 0.090 |
Why?
|
| Disability Evaluation | 2 | 2008 | 1828 | 0.090 |
Why?
|
| Animals | 27 | 2019 | 168788 | 0.090 |
Why?
|
| Mycobacterium avium Complex | 2 | 1999 | 60 | 0.090 |
Why?
|
| New York City | 2 | 2023 | 710 | 0.090 |
Why?
|
| Hippocampus | 3 | 2018 | 3676 | 0.090 |
Why?
|
| Cerebral Cortex | 2 | 2017 | 5709 | 0.090 |
Why?
|
| Regeneration | 1 | 2019 | 1485 | 0.090 |
Why?
|
| Lewy Body Disease | 1 | 2012 | 229 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2021 | 1480 | 0.090 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 365 | 0.090 |
Why?
|
| Survival Rate | 10 | 2020 | 12781 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 4 | 2005 | 287 | 0.090 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 2 | 1999 | 76 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 3 | 2002 | 821 | 0.090 |
Why?
|
| Pelvic Neoplasms | 1 | 2011 | 254 | 0.090 |
Why?
|
| Quinolines | 1 | 2014 | 730 | 0.090 |
Why?
|
| Myasthenia Gravis | 1 | 2012 | 201 | 0.090 |
Why?
|
| Nitriles | 1 | 2014 | 952 | 0.090 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2012 | 324 | 0.090 |
Why?
|
| Salvage Therapy | 2 | 2007 | 1275 | 0.090 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2018 | 627 | 0.090 |
Why?
|
| Injury Severity Score | 1 | 2012 | 1013 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 2 | 2012 | 1364 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 14 | 2022 | 35423 | 0.080 |
Why?
|
| Genome, Viral | 1 | 2013 | 667 | 0.080 |
Why?
|
| Hematoma | 1 | 2014 | 758 | 0.080 |
Why?
|
| Ear, External | 1 | 2009 | 161 | 0.080 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2008 | 61 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2012 | 931 | 0.080 |
Why?
|
| Hydatidiform Mole | 1 | 2011 | 279 | 0.080 |
Why?
|
| Breast Neoplasms | 6 | 2007 | 20817 | 0.080 |
Why?
|
| Seizures | 1 | 2021 | 2859 | 0.080 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 1504 | 0.080 |
Why?
|
| Apolipoprotein E3 | 2 | 2021 | 97 | 0.080 |
Why?
|
| Natural Language Processing | 1 | 2016 | 1040 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2007 | 2848 | 0.080 |
Why?
|
| Retinal Degeneration | 1 | 2012 | 415 | 0.080 |
Why?
|
| Cerebral Angiography | 1 | 2014 | 1285 | 0.080 |
Why?
|
| Cerebral Infarction | 1 | 2013 | 1010 | 0.080 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 2158 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 804 | 0.080 |
Why?
|
| Disease-Free Survival | 7 | 2014 | 6893 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 2291 | 0.080 |
Why?
|
| Acetylglucosaminidase | 1 | 2007 | 70 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 1602 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 7 | 2007 | 6172 | 0.080 |
Why?
|
| Recombination, Genetic | 1 | 2013 | 1586 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2006 | 2503 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 578 | 0.080 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 2732 | 0.080 |
Why?
|
| Papillomaviridae | 2 | 2004 | 1119 | 0.080 |
Why?
|
| Drainage | 1 | 2013 | 1141 | 0.080 |
Why?
|
| Sputum | 2 | 1999 | 476 | 0.080 |
Why?
|
| Mothers | 1 | 2018 | 2165 | 0.080 |
Why?
|
| Genes, Neoplasm | 1 | 2009 | 376 | 0.080 |
Why?
|
| Topotecan | 1 | 2007 | 138 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2022 | 11732 | 0.070 |
Why?
|
| False Negative Reactions | 2 | 2013 | 587 | 0.070 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2008 | 129 | 0.070 |
Why?
|
| Histological Techniques | 1 | 2007 | 198 | 0.070 |
Why?
|
| Life Tables | 1 | 2007 | 370 | 0.070 |
Why?
|
| Atrophy | 4 | 2016 | 1582 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 822 | 0.070 |
Why?
|
| Retinal Ganglion Cells | 1 | 2012 | 771 | 0.070 |
Why?
|
| Radiopharmaceuticals | 1 | 2017 | 2662 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 2737 | 0.070 |
Why?
|
| Presenilin-1 | 3 | 2019 | 635 | 0.070 |
Why?
|
| Dipeptides | 1 | 2009 | 409 | 0.070 |
Why?
|
| Tacrolimus | 1 | 2010 | 743 | 0.070 |
Why?
|
| Hospital Shared Services | 1 | 2006 | 16 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 8 | 2019 | 21824 | 0.070 |
Why?
|
| Gene Frequency | 4 | 2018 | 3588 | 0.070 |
Why?
|
| Tumor Microenvironment | 1 | 2018 | 3584 | 0.070 |
Why?
|
| Life Style | 1 | 2018 | 3835 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2012 | 1123 | 0.070 |
Why?
|
| Interferon-beta | 1 | 2008 | 323 | 0.070 |
Why?
|
| Telephone | 1 | 2009 | 617 | 0.070 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2008 | 472 | 0.070 |
Why?
|
| DNA-Binding Proteins | 5 | 2008 | 9647 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2004 | 704 | 0.070 |
Why?
|
| Gene Order | 1 | 2006 | 176 | 0.070 |
Why?
|
| Aneuploidy | 1 | 2009 | 530 | 0.070 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2008 | 236 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2020 | 7730 | 0.070 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2006 | 205 | 0.070 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 15538 | 0.070 |
Why?
|
| Mood Disorders | 2 | 2004 | 1106 | 0.070 |
Why?
|
| Twins, Dizygotic | 2 | 2009 | 236 | 0.070 |
Why?
|
| Transfection | 1 | 2013 | 5892 | 0.070 |
Why?
|
| Neuroma, Acoustic | 1 | 2009 | 451 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2013 | 6037 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 975 | 0.060 |
Why?
|
| Erythrocytes | 1 | 2014 | 2454 | 0.060 |
Why?
|
| Ependymoma | 1 | 2008 | 334 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2012 | 2539 | 0.060 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2005 | 182 | 0.060 |
Why?
|
| Dopamine | 1 | 2012 | 1591 | 0.060 |
Why?
|
| Esophagectomy | 2 | 2006 | 447 | 0.060 |
Why?
|
| Astrocytoma | 2 | 2006 | 789 | 0.060 |
Why?
|
| Protein Sorting Signals | 1 | 2005 | 281 | 0.060 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 791 | 0.060 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 13668 | 0.060 |
Why?
|
| Feasibility Studies | 3 | 2023 | 5076 | 0.060 |
Why?
|
| Celiac Disease | 1 | 2013 | 785 | 0.060 |
Why?
|
| Receptors, Cholinergic | 1 | 2005 | 238 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 4465 | 0.060 |
Why?
|
| Transcription Factors | 4 | 2011 | 12207 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2005 | 334 | 0.060 |
Why?
|
| Axons | 1 | 2012 | 1686 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2007 | 625 | 0.060 |
Why?
|
| Pneumocystis carinii | 1 | 2005 | 74 | 0.060 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 553 | 0.060 |
Why?
|
| Ubiquinone | 1 | 2005 | 188 | 0.060 |
Why?
|
| Ischemia | 1 | 2013 | 1914 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2011 | 733 | 0.060 |
Why?
|
| Transient Receptor Potential Channels | 2 | 2015 | 134 | 0.060 |
Why?
|
| Child | 11 | 2021 | 77679 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2018 | 2208 | 0.060 |
Why?
|
| Surgery Department, Hospital | 1 | 2005 | 175 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2007 | 567 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2014 | 11493 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5475 | 0.060 |
Why?
|
| Evolution, Molecular | 1 | 2013 | 1939 | 0.060 |
Why?
|
| Anxiety | 1 | 2018 | 4297 | 0.060 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 2538 | 0.060 |
Why?
|
| Artifacts | 1 | 2012 | 1903 | 0.060 |
Why?
|
| Chromosomes, Human | 1 | 2006 | 457 | 0.060 |
Why?
|
| Veterans | 1 | 2017 | 2519 | 0.060 |
Why?
|
| Feces | 2 | 1999 | 1402 | 0.060 |
Why?
|
| HIV Seropositivity | 2 | 2000 | 971 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2014 | 3443 | 0.060 |
Why?
|
| Pandemics | 2 | 2021 | 8387 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2018 | 1880 | 0.060 |
Why?
|
| Gene Deletion | 4 | 2005 | 2751 | 0.060 |
Why?
|
| Vitreous Body | 1 | 2005 | 389 | 0.060 |
Why?
|
| Perineum | 1 | 2005 | 211 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2020 | 12718 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2018 | 23337 | 0.060 |
Why?
|
| Anti-HIV Agents | 5 | 2000 | 4256 | 0.060 |
Why?
|
| Myocardial Infarction | 2 | 2022 | 11728 | 0.060 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 313 | 0.060 |
Why?
|
| Keratosis, Seborrheic | 1 | 2003 | 27 | 0.060 |
Why?
|
| Psychotic Disorders | 1 | 2018 | 3046 | 0.060 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 739 | 0.060 |
Why?
|
| Dementia, Multi-Infarct | 1 | 2002 | 12 | 0.060 |
Why?
|
| Oligodendroglia | 1 | 2006 | 519 | 0.060 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2006 | 336 | 0.060 |
Why?
|
| Nuclear Family | 1 | 2004 | 318 | 0.060 |
Why?
|
| Vulvar Diseases | 1 | 2003 | 61 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2005 | 1062 | 0.050 |
Why?
|
| Immunoglobulins | 1 | 2006 | 881 | 0.050 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2008 | 736 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 2 | 2005 | 1875 | 0.050 |
Why?
|
| Patient Transfer | 1 | 2009 | 761 | 0.050 |
Why?
|
| Homeostasis | 1 | 2013 | 3339 | 0.050 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 526 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 874 | 0.050 |
Why?
|
| Maternal Age | 1 | 2005 | 802 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3132 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 20123 | 0.050 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2003 | 123 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3239 | 0.050 |
Why?
|
| Philosophy | 1 | 2002 | 66 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 1097 | 0.050 |
Why?
|
| Hearing Loss | 1 | 2009 | 765 | 0.050 |
Why?
|
| Papillomavirus Infections | 2 | 2004 | 1587 | 0.050 |
Why?
|
| Enzyme Activation | 4 | 2012 | 3701 | 0.050 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2003 | 190 | 0.050 |
Why?
|
| Live Birth | 1 | 2005 | 512 | 0.050 |
Why?
|
| Cause of Death | 1 | 2012 | 3584 | 0.050 |
Why?
|
| Uterine Neoplasms | 1 | 2011 | 1513 | 0.050 |
Why?
|
| Factor VII | 1 | 2002 | 139 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1284 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2006 | 1616 | 0.050 |
Why?
|
| Hospitals, University | 1 | 2003 | 571 | 0.050 |
Why?
|
| Retina | 1 | 2012 | 2616 | 0.050 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 4837 | 0.050 |
Why?
|
| Sulfonylurea Compounds | 1 | 2022 | 204 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2023 | 292 | 0.050 |
Why?
|
| Pokeweed Mitogens | 1 | 2000 | 38 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2022 | 425 | 0.050 |
Why?
|
| Integrins | 1 | 2005 | 846 | 0.050 |
Why?
|
| Selection Bias | 1 | 2003 | 371 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2022 | 196 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3611 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 2005 | 332 | 0.050 |
Why?
|
| DNA Probes | 2 | 2012 | 560 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2021 | 2987 | 0.050 |
Why?
|
| Infarction | 1 | 2022 | 246 | 0.050 |
Why?
|
| Diagnosis, Differential | 7 | 2013 | 12961 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2022 | 229 | 0.050 |
Why?
|
| Streptokinase | 1 | 2000 | 188 | 0.050 |
Why?
|
| Glycoproteins | 2 | 2006 | 2263 | 0.050 |
Why?
|
| Calcium | 1 | 2013 | 5757 | 0.050 |
Why?
|
| Tumor Virus Infections | 1 | 2003 | 452 | 0.050 |
Why?
|
| Age Factors | 6 | 2018 | 18367 | 0.050 |
Why?
|
| Tetanus Toxoid | 1 | 2000 | 193 | 0.040 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 1061 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2005 | 1179 | 0.040 |
Why?
|
| Diet | 1 | 2018 | 7937 | 0.040 |
Why?
|
| Cross-Sectional Studies | 5 | 2016 | 25043 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4463 | 0.040 |
Why?
|
| Signal Transduction | 5 | 2012 | 23404 | 0.040 |
Why?
|
| Candida | 1 | 2000 | 172 | 0.040 |
Why?
|
| ROC Curve | 3 | 2013 | 3527 | 0.040 |
Why?
|
| Compensation and Redress | 1 | 2020 | 71 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2015 | 3311 | 0.040 |
Why?
|
| Zidovudine | 2 | 2000 | 620 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2021 | 40992 | 0.040 |
Why?
|
| Point Mutation | 1 | 2004 | 1624 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2002 | 615 | 0.040 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 431 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2006 | 528 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2005 | 941 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 4752 | 0.040 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2000 | 271 | 0.040 |
Why?
|
| Radionuclide Imaging | 2 | 2014 | 2030 | 0.040 |
Why?
|
| Body Temperature | 1 | 2022 | 777 | 0.040 |
Why?
|
| Hemorrhage | 2 | 2014 | 3461 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 2022 | 800 | 0.040 |
Why?
|
| Transportation | 1 | 2000 | 214 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2004 | 587 | 0.040 |
Why?
|
| DNA Mutational Analysis | 4 | 2012 | 4188 | 0.040 |
Why?
|
| Cell Division | 3 | 2001 | 4567 | 0.040 |
Why?
|
| Abdomen | 1 | 2005 | 1118 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2009 | 2575 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 892 | 0.040 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2000 | 423 | 0.040 |
Why?
|
| Liability, Legal | 1 | 2020 | 213 | 0.040 |
Why?
|
| Medulloblastoma | 1 | 2004 | 683 | 0.040 |
Why?
|
| Esthetics | 1 | 2000 | 306 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2005 | 1357 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2002 | 596 | 0.040 |
Why?
|
| Neopterin | 1 | 1997 | 56 | 0.040 |
Why?
|
| Didanosine | 1 | 1998 | 153 | 0.040 |
Why?
|
| Genetics, Medical | 1 | 2001 | 338 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2005 | 1660 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2005 | 12035 | 0.040 |
Why?
|
| Estradiol | 1 | 2005 | 2020 | 0.040 |
Why?
|
| Benzene Derivatives | 2 | 2009 | 54 | 0.040 |
Why?
|
| Ultrafiltration | 1 | 1997 | 57 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2009 | 3085 | 0.040 |
Why?
|
| Proteinuria | 1 | 2001 | 657 | 0.040 |
Why?
|
| Population Growth | 1 | 1997 | 52 | 0.040 |
Why?
|
| Alkenes | 2 | 2009 | 57 | 0.040 |
Why?
|
| Dialysis Solutions | 1 | 1997 | 39 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 3 | 2013 | 1080 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2006 | 2504 | 0.040 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 1999 | 209 | 0.040 |
Why?
|
| Population Surveillance | 2 | 2003 | 2616 | 0.040 |
Why?
|
| Genome | 1 | 2006 | 1808 | 0.040 |
Why?
|
| Fertilization in Vitro | 1 | 2005 | 1284 | 0.040 |
Why?
|
| Thiones | 1 | 2017 | 46 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 3747 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2018 | 1782 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2021 | 668 | 0.040 |
Why?
|
| Receptors, IgE | 1 | 1999 | 389 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 1998 | 246 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 559 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7879 | 0.040 |
Why?
|
| Pyrroles | 1 | 2023 | 1143 | 0.040 |
Why?
|
| Medical Records | 1 | 2022 | 1413 | 0.040 |
Why?
|
| Palmitates | 1 | 2017 | 74 | 0.040 |
Why?
|
| Hemodiafiltration | 1 | 2016 | 20 | 0.040 |
Why?
|
| Propranolol | 1 | 1998 | 502 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 2 | 2005 | 1831 | 0.040 |
Why?
|
| Stilbenes | 2 | 2009 | 156 | 0.040 |
Why?
|
| Photic Stimulation | 2 | 2014 | 2027 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 1999 | 793 | 0.040 |
Why?
|
| Evoked Potentials, Visual | 1 | 2019 | 427 | 0.030 |
Why?
|
| Stochastic Processes | 1 | 1997 | 344 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2012 | 1655 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2004 | 2948 | 0.030 |
Why?
|
| Hospitalization | 2 | 2013 | 10262 | 0.030 |
Why?
|
| Recurrence | 1 | 2008 | 8343 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2018 | 3420 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2002 | 1608 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2005 | 3748 | 0.030 |
Why?
|
| Receptors, Cell Surface | 2 | 2002 | 2867 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1999 | 992 | 0.030 |
Why?
|
| Disease | 1 | 2001 | 681 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2009 | 4553 | 0.030 |
Why?
|
| Triage | 1 | 2022 | 976 | 0.030 |
Why?
|
| Entorhinal Cortex | 1 | 2016 | 272 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1997 | 420 | 0.030 |
Why?
|
| Microdissection | 2 | 2005 | 152 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2005 | 1423 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 2018 | 13036 | 0.030 |
Why?
|
| Sarcoma | 1 | 2006 | 1897 | 0.030 |
Why?
|
| Partial Pressure | 1 | 2014 | 254 | 0.030 |
Why?
|
| Lameness, Animal | 1 | 2014 | 7 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1999 | 1267 | 0.030 |
Why?
|
| Urine | 1 | 2016 | 370 | 0.030 |
Why?
|
| Infant | 4 | 2021 | 35129 | 0.030 |
Why?
|
| Spirometry | 1 | 1997 | 864 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2015 | 643 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 1676 | 0.030 |
Why?
|
| Propensity Score | 1 | 2021 | 1781 | 0.030 |
Why?
|
| Calcium Sulfate | 1 | 2014 | 26 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2016 | 392 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 552 | 0.030 |
Why?
|
| Electroretinography | 1 | 2015 | 509 | 0.030 |
Why?
|
| Prostatic Neoplasms | 2 | 2000 | 11074 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 2289 | 0.030 |
Why?
|
| Oxyhemoglobins | 1 | 2014 | 216 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 10949 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 4455 | 0.030 |
Why?
|
| Dental Materials | 1 | 2014 | 108 | 0.030 |
Why?
|
| Injections, Intraventricular | 1 | 2013 | 230 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2014 | 173 | 0.030 |
Why?
|
| Neurites | 1 | 2015 | 388 | 0.030 |
Why?
|
| Mental Status Schedule | 1 | 2014 | 321 | 0.030 |
Why?
|
| Massachusetts | 2 | 2019 | 8663 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 8426 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 270 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2006 | 3528 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 1157 | 0.030 |
Why?
|
| Patient Preference | 1 | 2020 | 887 | 0.030 |
Why?
|
| Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2012 | 45 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 1999 | 1470 | 0.030 |
Why?
|
| Neoplasm Proteins | 2 | 2005 | 3703 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1640 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2001 | 1888 | 0.030 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2012 | 32 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2017 | 780 | 0.030 |
Why?
|
| Nephrology | 1 | 2016 | 263 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 895 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1998 | 1240 | 0.030 |
Why?
|
| DNA Repair Enzymes | 2 | 2007 | 349 | 0.030 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2012 | 319 | 0.030 |
Why?
|
| DNA, Viral | 2 | 2013 | 2226 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 2007 | 3079 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2000 | 2014 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2015 | 5180 | 0.030 |
Why?
|
| Maze Learning | 1 | 2014 | 478 | 0.030 |
Why?
|
| Parents | 1 | 2006 | 3407 | 0.030 |
Why?
|
| Telemedicine | 1 | 2009 | 2872 | 0.030 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 86 | 0.030 |
Why?
|
| Netherlands | 1 | 2017 | 2170 | 0.030 |
Why?
|
| Evoked Potentials | 1 | 2018 | 1057 | 0.030 |
Why?
|
| Sex Factors | 2 | 2018 | 10396 | 0.030 |
Why?
|
| Chromosomes, Human, Y | 1 | 2012 | 148 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12264 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2012 | 375 | 0.020 |
Why?
|
| Forecasting | 1 | 2020 | 2949 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1999 | 1838 | 0.020 |
Why?
|
| Intravitreal Injections | 1 | 2012 | 345 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 2505 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2014 | 853 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 434 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2012 | 296 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2017 | 1971 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 1083 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2013 | 981 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 2 | 2005 | 1799 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 1194 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 713 | 0.020 |
Why?
|
| Myelin Sheath | 1 | 2014 | 655 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 2875 | 0.020 |
Why?
|
| RNA, Viral | 1 | 1999 | 2902 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 155 | 0.020 |
Why?
|
| Educational Status | 1 | 2018 | 2539 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2012 | 802 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3474 | 0.020 |
Why?
|
| Capillaries | 1 | 2013 | 774 | 0.020 |
Why?
|
| Registries | 1 | 2006 | 8090 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2005 | 2425 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2012 | 964 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2015 | 14556 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 2557 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 913 | 0.020 |
Why?
|
| Fluorescent Dyes | 2 | 2009 | 1917 | 0.020 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 449 | 0.020 |
Why?
|
| Cyclic N-Oxides | 1 | 2009 | 78 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 865 | 0.020 |
Why?
|
| Flow Cytometry | 3 | 2006 | 5974 | 0.020 |
Why?
|
| Transgenes | 1 | 2012 | 1009 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2012 | 1137 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 5670 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 1434 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 4044 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 2161 | 0.020 |
Why?
|
| Overweight | 1 | 2020 | 2370 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 2540 | 0.020 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2012 | 555 | 0.020 |
Why?
|
| Lipocalins | 1 | 2009 | 170 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2009 | 323 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2012 | 688 | 0.020 |
Why?
|
| Arterioles | 1 | 2009 | 254 | 0.020 |
Why?
|
| Acute-Phase Proteins | 1 | 2009 | 262 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2009 | 3591 | 0.020 |
Why?
|
| Quinazolines | 1 | 2014 | 1356 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 12075 | 0.020 |
Why?
|
| Brain Stem | 1 | 2013 | 845 | 0.020 |
Why?
|
| Pattern Recognition, Automated | 1 | 2014 | 1005 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2015 | 1670 | 0.020 |
Why?
|
| Minocycline | 1 | 2009 | 163 | 0.020 |
Why?
|
| Neural Inhibition | 1 | 2012 | 602 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2001 | 5021 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2012 | 1726 | 0.020 |
Why?
|
| Dependovirus | 1 | 2012 | 706 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1998 | 5523 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2020 | 8321 | 0.020 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 587 | 0.020 |
Why?
|
| Neocortex | 1 | 2011 | 401 | 0.020 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2011 | 365 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 1563 | 0.020 |
Why?
|
| Biomedical Engineering | 1 | 2009 | 296 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2012 | 1770 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2014 | 3001 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2088 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3680 | 0.020 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 985 | 0.020 |
Why?
|
| Neurofibromin 2 | 1 | 2008 | 267 | 0.020 |
Why?
|
| Brain Concussion | 1 | 2018 | 1320 | 0.020 |
Why?
|
| Remote Consultation | 1 | 2009 | 238 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 4559 | 0.020 |
Why?
|
| Electromyography | 1 | 2012 | 1391 | 0.020 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2006 | 126 | 0.020 |
Why?
|
| Cerebral Arteries | 1 | 2009 | 494 | 0.020 |
Why?
|
| Matrix Metalloproteinases | 1 | 2009 | 391 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2006 | 6773 | 0.020 |
Why?
|
| Skin Window Technique | 1 | 2006 | 22 | 0.020 |
Why?
|
| Molecular Imaging | 1 | 2013 | 831 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 3842 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 1178 | 0.020 |
Why?
|
| Simvastatin | 1 | 2009 | 360 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2007 | 206 | 0.020 |
Why?
|
| Cerebellum | 1 | 2013 | 1490 | 0.020 |
Why?
|
| Computational Biology | 1 | 2018 | 3523 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5529 | 0.020 |
Why?
|
| Paxillin | 1 | 2005 | 86 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2014 | 1422 | 0.020 |
Why?
|
| Incidence | 2 | 2016 | 20945 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2018 | 5096 | 0.020 |
Why?
|
| Dental Implants | 1 | 2014 | 749 | 0.020 |
Why?
|
| Coenzymes | 1 | 2005 | 91 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 4665 | 0.020 |
Why?
|
| Hearing | 1 | 2009 | 482 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 400 | 0.020 |
Why?
|
| Integrin beta Chains | 1 | 2005 | 121 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 6612 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 520 | 0.020 |
Why?
|
| Phylogeny | 1 | 2013 | 2803 | 0.020 |
Why?
|
| Contrast Media | 1 | 2018 | 5300 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 6386 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 3328 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 2911 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2005 | 161 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2005 | 157 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2004 | 126 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 216 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 2272 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2005 | 436 | 0.020 |
Why?
|
| Genes, Immunoglobulin | 1 | 2005 | 291 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 2009 | 707 | 0.020 |
Why?
|
| Meninges | 1 | 2006 | 190 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2005 | 421 | 0.020 |
Why?
|
| Motor Activity | 1 | 2014 | 2714 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 2988 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 480 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 2005 | 376 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2004 | 335 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2727 | 0.010 |
Why?
|
| DNA | 2 | 2009 | 7303 | 0.010 |
Why?
|
| Syndecans | 1 | 2003 | 79 | 0.010 |
Why?
|
| Longevity | 1 | 2011 | 1069 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2014 | 2972 | 0.010 |
Why?
|
| Tomography, Optical Coherence | 1 | 2015 | 2657 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 8302 | 0.010 |
Why?
|
| Oxygen | 1 | 2014 | 4187 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2005 | 625 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2005 | 755 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 7659 | 0.010 |
Why?
|
| Cyclin E | 1 | 2003 | 172 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4201 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2007 | 1184 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2006 | 774 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2003 | 193 | 0.010 |
Why?
|
| Vindesine | 1 | 2002 | 12 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2005 | 15294 | 0.010 |
Why?
|
| Vitrectomy | 1 | 2005 | 365 | 0.010 |
Why?
|
| Syndecan-1 | 1 | 2003 | 165 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2006 | 2335 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2003 | 768 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 7179 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 4929 | 0.010 |
Why?
|
| Vasodilation | 1 | 2006 | 944 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2018 | 19227 | 0.010 |
Why?
|
| Colombia | 1 | 2002 | 258 | 0.010 |
Why?
|
| Synucleins | 1 | 2001 | 110 | 0.010 |
Why?
|
| Cranial Irradiation | 1 | 2004 | 401 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2005 | 13817 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2002 | 803 | 0.010 |
Why?
|
| Vaginal Smears | 1 | 2004 | 511 | 0.010 |
Why?
|
| Oleic Acid | 1 | 2001 | 85 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 2078 | 0.010 |
Why?
|
| Craniotomy | 1 | 2006 | 729 | 0.010 |
Why?
|
| Interferon Regulatory Factors | 1 | 2003 | 270 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1991 | 2942 | 0.010 |
Why?
|
| HIV-1 | 1 | 1999 | 6938 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2005 | 2256 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 644 | 0.010 |
Why?
|
| Zalcitabine | 1 | 2000 | 42 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 1114 | 0.010 |
Why?
|
| Internet | 1 | 2013 | 3063 | 0.010 |
Why?
|
| Autoantigens | 1 | 2005 | 892 | 0.010 |
Why?
|
| Cell Count | 1 | 2004 | 1854 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2005 | 18116 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2004 | 590 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2006 | 1004 | 0.010 |
Why?
|
| Base Sequence | 1 | 2011 | 12801 | 0.010 |
Why?
|
| Neprilysin | 1 | 2003 | 439 | 0.010 |
Why?
|
| Length of Stay | 1 | 2013 | 6308 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 2878 | 0.010 |
Why?
|
| Xenobiotics | 1 | 1999 | 73 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2003 | 835 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2014 | 3336 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2020 | 5787 | 0.010 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2001 | 300 | 0.010 |
Why?
|
| Cell Line | 2 | 2005 | 15999 | 0.010 |
Why?
|
| RNA | 1 | 2009 | 2749 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2012 | 5982 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1999 | 428 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 2255 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 4321 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2014 | 6546 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 2389 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1999 | 25618 | 0.010 |
Why?
|
| DNA Primers | 1 | 2003 | 2892 | 0.010 |
Why?
|
| Arginine | 1 | 2002 | 944 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 3846 | 0.010 |
Why?
|
| Mitogens | 1 | 1998 | 232 | 0.010 |
Why?
|
| Endarterectomy, Carotid | 1 | 2003 | 546 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2013 | 6259 | 0.010 |
Why?
|
| Cytosol | 1 | 2001 | 901 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 6474 | 0.010 |
Why?
|
| Age Distribution | 1 | 2004 | 2903 | 0.010 |
Why?
|
| Cysteine | 1 | 2002 | 874 | 0.010 |
Why?
|
| Obesity | 1 | 2020 | 12742 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1361 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1999 | 813 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 2422 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2005 | 3772 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 2839 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16365 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2012 | 6671 | 0.010 |
Why?
|
| Body Weight | 1 | 1987 | 4666 | 0.010 |
Why?
|
| Homozygote | 1 | 2001 | 1786 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 3800 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6367 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 4217 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 7799 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1999 | 547 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 2236 | 0.010 |
Why?
|
| DNA Helicases | 1 | 2001 | 861 | 0.010 |
Why?
|
| Heterozygote | 1 | 2002 | 2805 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 1642 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 2005 | 1203 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2001 | 1143 | 0.010 |
Why?
|
| alpha-Synuclein | 1 | 2001 | 725 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2005 | 4156 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 2211 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 2003 | 1475 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2005 | 2895 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2006 | 8628 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 16687 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2003 | 11478 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 3256 | 0.010 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2003 | 1186 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 1378 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2006 | 2790 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 13096 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 4742 | 0.010 |
Why?
|
| Cell Separation | 1 | 1998 | 1751 | 0.010 |
Why?
|
| Mitochondria | 1 | 2005 | 3520 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2006 | 3863 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2004 | 2019 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 5853 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1998 | 1836 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 10480 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 11007 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2005 | 9147 | 0.010 |
Why?
|
| Lipids | 1 | 2001 | 3305 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2000 | 6485 | 0.010 |
Why?
|
| Pregnancy | 1 | 2011 | 29142 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 24273 | 0.010 |
Why?
|
| Protein Binding | 1 | 2001 | 9392 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1987 | 198 | 0.000 |
Why?
|
| Anticoagulants | 1 | 1998 | 4599 | 0.000 |
Why?
|
| Body Height | 1 | 1987 | 1576 | 0.000 |
Why?
|